Stop and Smell the ROSis: Translating Molecular Results Into Actionable Pharmacy Practice in ROS1-Rearranged NSCLC

Program Description

Non‒small cell lung cancer (NSCLC) management is increasingly defined by precision medicine, and comprehensive molecular profiling at diagnosis and upon disease progression is the cornerstone for identifying actionable oncogenic drivers and emerging resistance mutations. ROS1 rearrangements represent a well-defined yet uncommon molecular subset, accounting for roughly 1% to 2% of NSCLC cases. The increasing availability of ROS1-targeted therapies requires that oncology pharmacists expertly navigate complex molecular testing and targeted therapy sequencing, particularly for the distinct subset of patients with NSCLC with ROS1 rearrangements. This activity will explore approaches for oncology pharmacists to operationalize next-generation sequencing data, focusing on interpreting ROS1 fusions and key resistance mutations to guide optimal treatment selection. A major focus will address the challenge of treatment sequencing, offering comparative analyses of first-generation and next-generation ROS1-targeted therapies based on their efficacy, central nervous system penetration, and resistance coverage in patients with disease progression. The program will also delve into mechanism-based toxicity management, providing insights on interventions and strategies for monitoring and mitigating agent-specific adverse effects to support the delivery of patient counseling pearls and improved care throughout the entire NSCLC treatment continuum. Participants will have the opportunity to examine patient case scenarios and apply evidence-based sequencing strategies.

Target audience: Oncology pharmacists

Type of activity: Application
Release date: January 30, 2026
Expiration date: January 30, 2027
Learner level: Advanced
Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Examine molecular and resistance testing results to support biomarker-directed selection and sequencing of ROS1-targeted therapies throughout the treatment continuum in non‒small cell lung cancer (NSCLC)
• Analyze the efficacy, safety, and resistance profiles of available and emerging ROS1-targeted therapies to inform individualized selection and sequencing across the NSCLC continuum
• Employ mechanism-driven strategies to anticipate, monitor, and manage toxicities associated with ROS1-targeted therapies to optimize adherence and sustain long-term treatment benefit